MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/qai.0000000000002072

Медицинская библиотека · Journal of acquired immune deficiency syndromes (1999) · 2019

Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial.

Sebikari Dorothy, Farhad Mona, Fenton Terry, Owor Maxensia, Stringer Jeffrey S A, Qin Min, Chakhtoura Nahida, Chi Benjamin H, Saidi Friday, Nevrekar Neetal, Violari Avy, Chipato Tsungai, McIntyre James A, Moodley Dhayendre, Taha Taha E, Theron Gerhard, Fowler Mary Glenn

СтатьяРандомизированное исследованиеПоддержка NIH: внешняя программаПеревод в очереди

Аннотация

BACKGROUND

In the multicountry PROMISE 1077BF/1077FF trial, the risk of low birth weight (LBW; <2500 g) and preterm delivery (PTD; <37 weeks) was significantly higher among women initiating a protease inhibitor-based antiretroviral treatment (ART) regimen than those receiving ZDV alone. Among those assigned to a protease inhibitor regimen, tenofovir/emtricitabine was associated with the more severe outcomes of very LBW (<1500 g) and very PTD (<34 weeks) compared with zidovudine/lamivudine.

METHODS

We used multivariate logistic regression to further explore these treatment findings, taking into account demographic baseline clinical and postentry obstetrical factors. We evaluated individual adverse outcomes and composites that included stillbirth and early loss/spontaneous abortion.

RESULTS

Among 3333 women delivering at least 1 live infant, median maternal age at enrollment was 26 years; 661 (20%) were primiparous, and 110 (3.3%) reported at least 1 previous PTD. Seventeen percent of newborns were LBW, 1% were very LBW, 17% had PTD, and 3% had very PTD. Treatment allocation remained strongly associated with multiple adverse outcomes after controlling for other risk factors with both ART regimens exhibiting increased risk relative to ZDV alone. Other risk factors remaining significant in at least one of the multivariate models included the following: country, gestational age at entry, maternal age, maternal body mass index, previous PTD, history of alcohol use, baseline HIV viral titer, multiple gestation, and several obstetric risk factors.

CONCLUSIONS

ART effects on adverse pregnancy outcomes reported in the randomized PROMISE trial remained strongly significant even after controlling for demographic, baseline clinical, and obstetrical risk factors, which were also associated with these outcomes.

Для цитирования: Sebikari Dorothy, Farhad Mona, Fenton Terry, Owor Maxensia, Stringer Jeffrey S A, Qin Min, Chakhtoura Nahida, Chi Benjamin H, Saidi Friday, Nevrekar Neetal, Violari Avy, Chipato Tsungai, McIntyre James A, Moodley Dhayendre, Taha Taha E, Theron Gerhard, Fowler Mary Glenn. Risk Factors for Adverse Birth Outcomes in the PROMISE 1077BF/1077FF Trial.. Journal of acquired immune deficiency syndromes (1999). 2019. DOI: 10.1097/qai.0000000000002072.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.